Visual function in multiple sclerosis patients treated with Fingolimob during two years of follow‐up

• Published in: Acta ophthalmologica (Oxford, England) Vol. 95; no. S259
• Main Authors: Cipres Alastuey, M, Garcia Martin, E, Bambo Rubio, MP, Vilades Palomar, E, Satue Palacian, M, Obis Alfaro, J, Rodrigo Sanjuan, MJ, Orduna Hospital, E
• Format: Journal Article
• Language: English
• Published: Malden Wiley Subscription Services, Inc 01.09.2017
• Subjects: Acuity; Multiple sclerosis; Neurodegenerative diseases; Neurological diseases; Quality of life; Sclerosis; Vision; Visual acuity; Visual observation; Visual perception
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/j.1755-3768.2017.0T037

Purpose To evaluate visual function changes in multiple sclerosis (MS) patients treated with Fingolimob during two years. Methods A total of 31 eyes of 16 MS patients that were going to start Fingolimob treatment were included. All of them underwent an ophtalmic examination including best corrected visual acuity (BCVA) using ETDRS optotype with 100%, 2,5% and 1.25% contrast; contrast sensitivity using CSV 100 E and Pelli‐Robson tests and cromatic vision using Farsworth and Lanthony D15 tests. Quality of life was evaluated by the MSQOL questionnaire. The same protocol was repeated 2 years later. Results A significant reduction of visual acuity was observed after two years of follow‐ up in 2.5% (0.33 ± 0.023 vs 0.39 ± 0.16; p < 0.001) and 1.25% (0.43 ± 0.05 vs 0.54 ± 0.22; p < 0.001) contrasts. All CSV frequencies showed a significant decrease except 18 cpd (3 cpd: 1.78 vs 1.73 ± 0.17; 6 cpd: 1.94 ± 0.17 vs 1.85 ± 0.24; 12 cpd: 1.69 vs 1.39 ± 0.37; p < 0.001). A progresive reduction in chromatic vision (Farnsworth and Lanthony test, p < 0.001) was also found. MSQOL‐54 questionnarie result was significatly lower after two years in physical (p = 0.023) and mental (p = 0.032) health sections. Conclusions MS patients treated with Fingolimob present progressive changes in visual acuity, contrast sensivity, and chromatic vision. Visual function tests may be an useful tool to evaluate the progression of neurodegenerative diseases and treatment effectiveness.